Nafamostat mesylate

Research use only, not for human use.

Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.

Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.

Cell Viability Assay Cell Line:MDAPanc-28 cells Concentration:80 μg/mL Incubation Time:24 h, 48 h Result:Substantially reduced the cell viability of MDAPanc-28 cells at both 24 hours and 48 hours.Cell Invasion Assay Cell Line:Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.Panc-1 cells Concentration:0.1 μM, 1 μM, 10 μM Incubation Time:24 h Result:Observed significant inhibition in Panc-1-Try clones at concentrations as low as 0.1 mM.Western Blot Analysis Cell Line:MDAPanc-28 cells Concentration:10 μg/mL, 20 μg/mL ,40 μg/mL, 80 μg/mL Incubation Time:3 h, 8 h, 24 h, 48 h Result:Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.Inhibited phosphorylation of IκBα in a time-dependent manner.

Animal Model:A129 miceDosage:10 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Exhibit delayed lethality and improved survival (40%).Animal Model:Balloon injury of the rat carotid wall Dosage:0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline)Administration:Intraperitoneal injection (i.p.)Result:Showed smaller ratios of the neointima/medial area.Showed positive but reduced immunoreactivity of the cells in the neointimal.

Coahibitor | FUT 175 | Nafamastat

Proteasome/Ubiquitin

Serine Protease

Serine Protease

Cardiovascular Disease

——

82956-11-4

539.58

C19H17N5O2·2CH4O3S

>98% (HPLC)

Water: 53 mg/mL (98.22 mM); DMSO: 20 mg/mL (37.06 mM)

CS(O)(=O)=O.CS(O)(=O)=O.NC(N)=NC1=CC=C(C=C1)C(=O)OC1=CC2=C(C=C1)C=C(C=C2)C(N)=N

——

(-20℃)

With Ice Pack

≥ 2 years